Skip to main content
. 2016 Jun 17;5(5):354–363. doi: 10.1002/cpdd.269

Figure 1.

Figure 1

Mean plasma (average concentration)–time profile of pegylated filgrastim (linear plot) following a fixed single subcutaneous injection of 6 mg of the proposed pegfilgrastim biosimilar or the reference product pegfilgrastim in healthy volunteers. Insert displays 0–96 hours.